Korsana Biosciences, Inc.: Wells Fargo initiates coverage with overweight rating and target price $44
KRSA•Wells Fargo initiated coverage of Korsana Biosciences, Inc. with an overweight rating and a $44 target price.
Related News
Avnet Inc.: BofA Global Research cuts price objective to $110 from $115
AVT•
Applied Materials: BofA Global Research cuts price objective to $520 from $650
AMAT•
Netease Cloud Music and Sony Music Entertainment announce strategic multi-year licensing agreement
SONY•
Jaguar Health to host webcast on Q3 financial results
JAGX•
Silexion Therapeutics Q3 net loss narrows 24% year over year to $2.5 million
SLXN•